Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Message for Thtx

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Sep 01, 2021 10:07am

129 Views

Post# 33793774

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Message for Thtx

Not to mention all of them are in negative territory this year except bycy.

qwerty22 wrote:

Thtx have 5 PRs in 2021 announcing attendance at investor conferences/events. They did posters in at least two scientific conferences and they did their own KOL event. They put out 30 PRs

I don't see 89bio doing much more than that. 89bio have put out half the number of PRs this year than thtx and attended 7 investor conferences.

ADC therapeutics has 7 active clinical trial. They just launched their first approved drug. That's substantially more stuff to talk about. They still only did 7 investor conferences and put out 26 PRs in 2021.

Its crazy you can't help throwing in two fraudsters.

I don't see these other companies doing a whole lot more than thtx, I think you've become jaundiced.

scarlet1967 wrote: They never told investors when both MD Anderson and Karmanos start enrolling patients, the interview with Dr. Shah describing their PDC as small missiles attacking cancer cells is on Gettysburg’s website but not on THTX’s.
The list below is few companies which frequently attend high profile conferences and update their investors re enrollment been finished, patients been dosed, updates on results in timely fashion etc. Yes it includes both Seson and CYDY. Now I never asked the company to go as far as CYDY or falsify trials but again we are talking about one contrast to the other. They have not been attending any high profile conferences this year apart from one where CFO presented a preclinical cancer abstract and that’s about it, the rest were fire chats with concord, the Water Tower Research and LSA webinar, the last two were supposed to be their retail approach. Water tower has very few follower and LSA is mostly approaching institutional investors.
The CEO of HEPA goes on well followed seeking alpha, the CEO of CYDY attended multiple times on Dr.been (YouTube) with tens of thousands viewings each episode etc.
Point is there is a reason why they have 900 followers on Stocktwits versus others multiples of that, again I am not sure why and what stops them to be far more proactive on both retail and institutional sides, is it liability issues well have a disclaimer before your presentation is it ego or laziness well would those stop them from doing it if their salaries and bonuses well depending on share price performance?
It is not about what you say and how you say only but where you say it and how often you say it, it is called marketing.
Press Releases | 89bio, Inc.

https://ir.cohbar.com/press-releases

https://investors.bicycletherapeutics.com/events-and-presentations

https://hepionpharma.com/about/newsroom/

https://ir.adctherapeutics.com/press-releases/default.aspx

https://ir.sesenbio.com/

https://www.cytodyn.com/newsroom/press-releases